Advertisement


Andrew Seidman, MD, and Hope Rugo, MD: Less is More: Scaling Back Breast Cancer Treatment

2015 San Antonio Breast Cancer Symposium

Advertisement

Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Hope S. Rugo, MD, of the University of California, San Francisco, discuss findings on de-escalating systemic therapy for breast cancer (Abstract ES6-3).



Related Videos

Breast Cancer

Andrew Seidman, MD, and Sabine Seisling, PhD, on Early-Stage Breast Cancer Outcomes: Breast-Conserving Therapy vs Mastectomy

Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Sabine Siesling, PhD, of the Netherlands Comprehensive Cancer Organization, discuss the improved overall survival after 10 years in women who received breast-conserving surgery compared with those who received mastectomy with radiation treatment. (Abstract S3-05)

Breast Cancer

Matthew J. Ellis, PhD, FRCP: Update on Translational Research

Matthew J. Ellis, PhD, FRCP, of the Baylor College of Medicine, gives his expert perspective on this evolving area of research.

Breast Cancer

Mitchell Dowsett, PhD, on Estimating Residual Distant Recurrence Risk: EndoPredict and Oncotype DX

Mitchell Dowsett, PhD, of the Royal Marsden Hospital discusses the EndoPredict test, which has improved performance compared with the widely used Oncotype Dx test (Abstract S3-01).

Breast Cancer

Andrew Seidman, MD, and Hope Rugo, MD, on Advanced Breast Cancer: KEYNOTE-028 Study Results

Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Hope S. Rugo, MD, of the University of California, San Francisco, discuss preliminary efficacy and safety findings of pembrolizumab in patients with PD-L1–positive, estrogen receptor-positive/HER2-negative disease. (Abstract S5-07)

Breast Cancer

Andrew Seidman, MD, and Norman Wolmark, MD, on NSABP Clinical Trials and Management of Early Breast Cancer

Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Norman Wolmark, MD, of Allegheny General Hospital, discuss the landmark trials of NSABP that have led to profound changes in breast cancer treatment. (Abstract ML-1)

Advertisement

Advertisement




Advertisement